Inoue Y, Kaku K, Kaneko T, Matsumura S, Nakayama H, Yoshizaki Y, Ando S, Inoue M, Hatao M
Third Department of Internal Medicine, Yamaguchi University School of Medicine, Japan.
J Int Med Res. 1996 Jan-Feb;24(1):138-46. doi: 10.1177/030006059602400118.
In this multicentre, non-randomized clinical study, 35 hypertensive patients with concomitant non-insulin-dependent diabetes mellitus were treated with the selective alpha 1 adrenoceptor blocker doxazosin mesilate for 24 weeks, either alone or together with existing antihypertensive therapy. The effects of the drug on blood pressure, glucose and lipid metabolism were examined. Daily administration of 0.5-8 mg doxazosin caused a significant reduction in both systolic and diastolic blood pressure decreased from 172 +/- 15/90 +/- 11 mmHg at the beginning, to 149 +/- 19/80 +/- 12 mmHg at the end of the trial. Heart rate was not affected. The plasma glucose level showed no change, whereas the haemoglobin A1c level decreased significantly from 7.4 +/- 1.2% to 7.1 +/- 1.2% (P < 0.01). Total and high-density lipoprotein cholesterol levels remained unchanged. The triglycerides level, however, decreased from 113 +/- 54 mg/dl at the beginning to 98 +/- 49 mg/dl at the end of the trial (P < 0.05). In a subgroup of patients, who showed hypercholesterolaemia ( > or = 220 mg/dl, n = 9) at the beginning, the total cholesterol level decreased from 252 +/- 33 mg/dl to 220 +/- 33 mg/dl (P < 0.05). Two patients complained of abdominal fullness or diarrhoea, but both were easily manageable. The results indicate that doxazosin is effective and safe in the treatment of hypertension in non-insulin-dependent diabetics and does not affect glucose metabolism. As for lipid metabolism in non-insulin-dependent diabetic patients, doxazosin seems to have a beneficial effect.
在这项多中心、非随机临床研究中，35例伴有非胰岛素依赖型糖尿病的高血压患者接受了选择性α1肾上腺素能受体阻滞剂甲磺酸多沙唑嗪治疗，为期24周，治疗方式为单独用药或与现有的抗高血压治疗联合使用。研究考察了该药物对血压、血糖和脂质代谢的影响。每日服用0.5 - 8毫克多沙唑嗪可使收缩压和舒张压显著降低，收缩压从开始时的172±15/90±11毫米汞柱降至试验结束时的149±19/80±12毫米汞柱。心率未受影响。血浆葡萄糖水平无变化，而糖化血红蛋白水平从7.4±1.2%显著降至7.1±1.2%（P<0.01）。总胆固醇和高密度脂蛋白胆固醇水平保持不变。然而，甘油三酯水平从开始时的113±54毫克/分升降至试验结束时的98±49毫克/分升（P<0.05）。在初始时表现为高胆固醇血症（≥220毫克/分升，n = 9）的患者亚组中，总胆固醇水平从252±33毫克/分升降至220±33毫克/分升（P<0.05）。两名患者抱怨有腹部胀满或腹泻，但均易于处理。结果表明，多沙唑嗪在治疗非胰岛素依赖型糖尿病患者的高血压方面有效且安全，并且不影响葡萄糖代谢。对于非胰岛素依赖型糖尿病患者的脂质代谢，多沙唑嗪似乎具有有益作用。
